Aptamer BC 007’s Affinity to Specific and Less-Specific Anti-SARS-CoV-2 Neutralizing Antibodies
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: Viruses, Band 13, Ausgabe 5, 2021
- Event
-
Veröffentlichung
- (where)
-
Berlin
- (who)
-
Humboldt-Universität zu Berlin
- (when)
-
2021
- Creator
-
Weisshoff, Hardy
Haberland, Annekathrin
Krylova, Oxana
Nikolenko, Heike
Göttel, Peter
Dallmann, Andre
Müller, Johannes
- DOI
-
10.3390/v13050932
- URN
-
urn:nbn:de:kobv:11-110-18452/23839-4
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
25.03.2025, 1:42 PM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Weisshoff, Hardy
- Haberland, Annekathrin
- Krylova, Oxana
- Nikolenko, Heike
- Göttel, Peter
- Dallmann, Andre
- Müller, Johannes
- Humboldt-Universität zu Berlin
Time of origin
- 2021
Other Objects (12)
Bi- and Multi-specific Antibodies
Identification and characterization of new broadly neutralizing and potent HIV-1-antibodies by Env-specific B cell sorting
The dual aptamer approach : rational design of a high-affinity FAD aptamer
Development of conformation specific Amyloid-beta antibodies
Kinetics of Nucleo- and Spike Protein-Specific Immunoglobulin G and of Virus-Neutralizing Antibodies after SARS-CoV-2 Infection
Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus
Humans naturally acquire cross-specific anti-glycan antibodies
Development of SARS-CoV-2 Specific IgG and Virus-Neutralizing Antibodies after Infection with Variants of Concern or Vaccination
Neutralizing antibodies as tools for structure-based vaccine design
Protection from Cytomegalovirus Infection by Glycoprotein-specific Monoclonal Antibodies
Development of conformation specific Amyloid-β [Amyloid-beta] antibodies
Protection from cytomegalovirus infection by glycoprotein-specific monoclonal antibodies
Bi- and Multi-specific Antibodies
Identification and characterization of new broadly neutralizing and potent HIV-1-antibodies by Env-specific B cell sorting
The dual aptamer approach : rational design of a high-affinity FAD aptamer
Development of conformation specific Amyloid-beta antibodies
Kinetics of Nucleo- and Spike Protein-Specific Immunoglobulin G and of Virus-Neutralizing Antibodies after SARS-CoV-2 Infection
Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus
Humans naturally acquire cross-specific anti-glycan antibodies
Development of SARS-CoV-2 Specific IgG and Virus-Neutralizing Antibodies after Infection with Variants of Concern or Vaccination
Neutralizing antibodies as tools for structure-based vaccine design
Protection from Cytomegalovirus Infection by Glycoprotein-specific Monoclonal Antibodies
Development of conformation specific Amyloid-β [Amyloid-beta] antibodies
Protection from cytomegalovirus infection by glycoprotein-specific monoclonal antibodies
Bi- and Multi-specific Antibodies
Identification and characterization of new broadly neutralizing and potent HIV-1-antibodies by Env-specific B cell sorting
The dual aptamer approach : rational design of a high-affinity FAD aptamer
Development of conformation specific Amyloid-beta antibodies
Kinetics of Nucleo- and Spike Protein-Specific Immunoglobulin G and of Virus-Neutralizing Antibodies after SARS-CoV-2 Infection
Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus
Humans naturally acquire cross-specific anti-glycan antibodies
Development of SARS-CoV-2 Specific IgG and Virus-Neutralizing Antibodies after Infection with Variants of Concern or Vaccination
Neutralizing antibodies as tools for structure-based vaccine design
Protection from Cytomegalovirus Infection by Glycoprotein-specific Monoclonal Antibodies
Development of conformation specific Amyloid-β [Amyloid-beta] antibodies